You just read:

ActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten

News provided by

ActoBio Therapeutics, Inc.

Aug 19, 2019, 07:30 ET